Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Alterity Therapeutics has appointed David Stamler to CEO. Formerly, Stamler was Alterity’s chief medical officer and senior vice president of clinical development.
Asklepios BioPharmaceutical has appointed Katherine High to president of therapeutics. Prior to this appointment, High was a visiting professor at Rockefeller University.
Aviceda Therapeutics has appointed Mohamed Genead to CEO, David Callanan to chief medical officer, Derek Kunimoto to chief operating officer and Christopher Scott to chief scientific officer. Genead was formerly the chief medical officer at GenSight Biologics, Callanan is clinical professor at the University of Texas Southwestern Medical School, Kunimoto will continue to serve as managing partner at Retinal Consultants of Arizona and Retinal Research Institute and Scott will continue to serve as director of the Patrick G Johnston Centre for Cancer Research and Cell Biology at Queen’s University Belfast.
Robert Williamson has assumed the CEO position at BioTheryX. Prior to this appointment, Williamson was CEO of PharmAkea and ATXCo.
Becker Hewes, senior vice president of clinical development at Blueprint Medicines, has been named chief medical officer of the company. Blueprint has also announced that Andy Boral, the company’s former chief medical officer, will transition to executive vice president of clinical development.
French biotech DEINOVE has appointed Alexis Rideau to CEO. Previously, Rideau was the strategy partnership manager at BIOASTER.
DTx Pharma has promoted Bryan Laffitte from vice president of biology to chief scientific officer. Prior to joining DTx, Laffitte was vice president of biology at Inception Therapeutics.
Eleusis has named David Nichols the director of molecular pharmacology. Nichols will continue to serve in his most recent position as an adjunct professor at the University of North Carolina Chapel Hill.
Mark Gelder has been promoted from vice president of medical affairs to chief medical officer at Elevar Therapeutics.
Former senior vice president and head of development of Nektar Therapeutics, Wei Lin, has been named the newest chief medical officer of Erasca.
Immunovant has appointed Rita Jain to the role of chief medical officer. Most recently, Jain was senior vice president and chief medical officer of Akebia Therapeutics.
Louis Pascarella has taken the helm of Innocoll as its newest CEO. Pascarella most recently served as the U.S. head of commercial operations at Novo Nordisk.
Eugene Schneider has been named executive vice president and chief clinical development officer of Ionis Pharmaceuticals. Prior to this appointment, Schneider was the head of clinical development at Ionis.
Atsushi Sugita has been named president and CEO of Japanese pharmaceutical company Maruho. Most recently, Sugita served as marketing director at Janssen.
Dave Marek has been appointed CEO of Myovant Sciences. Most recently, Marek was the chief commercial officer at Axsome Therapeutics.
Michael Goldstein, chief medical officer of Ocular Therapeutix, has been promoted to president of ophthalmology.
Patrick van der Loo has been named by Pfizer as the company’s regional president for Africa and the Middle East (AfME) region. Van der Loo was most recently the developed Asia cluster lead and general manager for Pfizer’s hospital business unit.
Ramona Doyle has been named chief medical officer of digital biology company Recursion. Doyle is the former chief medical officer of Blade Therapeutics.
Synthon has named Anish Mehta the company’s new CEO. Mehta was previously the CEO of Theramex prior to joining Synthon.
Versameb has found its newest CEO in Klaas Zuideveld, the company’s former chief development officer. Also, Friedrich Metzger was hired by Versameb to take on the role of chief scientific officer. Previously, Metzger was head of discovery of rare diseases at Roche.